Literature DB >> 12583842

Neurologic complications of chemotherapy for children with cancer.

Alyssa T Reddy1, Kerry Witek.   

Abstract

Survival rates for children with cancer have increased dramatically over the past few decades. Development of new chemotherapeutic agents and the expanded use of older agents have had a major impact on this celebrated improvement. Chemotherapy can have, however, significant toxicity on the nervous system. The most common neurologic complications involve acute alterations in consciousness, leukoencephalopathy, seizures, cerebral infarctions, paralysis, neuropathy, and ototoxicity. Most of the information on toxicity comes from prospective reports and the adult patient population. Methotrexate, cyclosporin, and platinum compounds are the most frequently cited. No prospective studies have been done to evaluate chemotherapy-induced neurotoxicity in the pediatric population, and the exact incidence of such complications is unknown. Such investigation is greatly needed, as it may lead to a better understanding of how chemotherapy affects the nervous system and ultimately help develop more strategies to prevent drug-related neurotoxicity in pediatric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12583842     DOI: 10.1007/s11910-003-0065-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  38 in total

Review 1.  [Neurologic complications during chemotherapy of children with acute lymphoid leukemia].

Authors:  M Kardos; E Grexa; P Kajtár
Journal:  Orv Hetil       Date:  1992-05-03       Impact factor: 0.540

2.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.

Authors:  D H Mahoney; J J Shuster; R Nitschke; S J Lauer; C P Steuber; N Winick; B Camitta
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  Parkinsonism during cyclosporine treatment.

Authors:  P H Wasserstein; L S Honig
Journal:  Bone Marrow Transplant       Date:  1996-09       Impact factor: 5.483

Review 4.  Cyclosporine neurotoxicity: a review.

Authors:  J M Gijtenbeek; M J van den Bent; C J Vecht
Journal:  J Neurol       Date:  1999-05       Impact factor: 4.849

5.  Electroencephalogram changes secondary to asparaginase.

Authors:  J M Moure; J P Whitecar; G P Bodey
Journal:  Arch Neurol       Date:  1970-10

6.  Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma.

Authors:  D Re; A Schwenk; P Hegener; S Bamborschke; V Diehl; H Tesch
Journal:  Ann Oncol       Date:  2000-02       Impact factor: 32.976

7.  Cerebrovascular accidents in children with cancer.

Authors:  R J Packer; L B Rorke; B J Lange; K R Siegel; A E Evans
Journal:  Pediatrics       Date:  1985-08       Impact factor: 7.124

8.  Childhood acute lymphocytic leukemia: study VIII.

Authors:  R J Aur; J V Simone; M S Verzosa; H O Hustu; L F Barker; D P Pinkel; G Rivera; G V Dahl; A Wood; S Stagner; C Mason
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

9.  Multifocal inflammatory leukoencephalopathy associated with levamisole therapy.

Authors:  D W Kimmel; E F Wijdicks; M Rodriguez
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

Review 10.  Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.

Authors:  J Pelgrims; F De Vos; J Van den Brande; D Schrijvers; A Prové; J B Vermorken
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  8 in total

Review 1.  [Acute central nervous symptoms in oncologic patients].

Authors:  K Orlopp; I G H Schmidt-Wolf; H Urbach; U Schlegel
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

Review 2.  [White matter alterations after chemotherapy and radiation].

Authors:  A Simgen
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

3.  Ages and Stages Questionnaires-3 developmental screening of infants and young children with cancer.

Authors:  Troy C Quigg; Arash Mahajerin; Paula D Sullivan; Kamnesh Pradhan; Nerissa S Bauer
Journal:  J Pediatr Oncol Nurs       Date:  2013-07-18       Impact factor: 1.636

4.  Hemorrhagic and ischemic stroke in children with cancer.

Authors:  Corina Noje; Kenneth Cohen; Lori C Jordan
Journal:  Pediatr Neurol       Date:  2013-08-12       Impact factor: 3.372

5.  Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brain.

Authors:  Najeeb Ullah; Hae Young Lee; Muhammad Imran Naseer; Ikram Ullah; Joo Won Suh; Myeong Ok Kim
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

6.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

Authors:  Joerg Dietrich; Ruolan Han; Yin Yang; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2006

7.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Authors:  Ruolan Han; Yin M Yang; Joerg Dietrich; Anne Luebke; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2008-04-22

8.  Neurotoxicity of cancer chemotherapy.

Authors:  Miyoung Yang; Changjong Moon
Journal:  Neural Regen Res       Date:  2013-06-15       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.